Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
CDAD is the major known cause of antibiotic-induced diarrhea and colitis, and the disease is thought to result from persistent disruption of commensal gut microbiota.Bacteriotherapy by way of fecal transplantation can be used to treat recurrent CDAD and is thought to re-establish the normal colonic microflora.However, limitations of conventional microbiologic techniques have until recently precluded testing of this idea.In this study we used T-RFLP and 16S rRNA gene sequencing approaches to characterize the bacterial composition of the colonic microflora in a patient suffering from recurrent CDAD, before and after treatment by fecal transplantation from a healthy donor.While the patient's residual colonic microbiota, prior to therapy, was deficient in members of the bacterial divisions-Firmicutes and Bacteriodetes, transplantation had a dramatic impact on the composition of the patient's gut microbiota.By 14 days post transplantation, the fecal bacterial composition of the recipient was highly similar to the donor and was dominated by Bacteroides spp.strains and an uncharacterized butyrate producing bacterium.The change in bacterial composition was accompanied by resolution of the patient's symptoms.The striking similarity of the recipient's and donor's intestinal microbiota following bacteriotherapy suggests that the donor's bacteria quickly occupied their requisite niches, resulting in restoration of both the structure and function of the microbial communities present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Multiple studies have demonstrated remarkable effectiveness of FMT in cases of recurrent and refractory CDI, which may be attributed to sustained restoration of the normal microbiota after FMT.22,23”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, studies have demonstrated that patients suffering from recurrent CDI are deficient in phyla of bacteria normally dominant in the colon6,45 (Figure 1).”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
In the citing paper
“Moreover, the restoration of more typical microbial communities, which come to resemble those of the donor post-transplant, persists in a durable fashion after FMT.6, 7”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
In the citing paper
“FMT appears to result in durable engraftment of new species from donor as well as augmentation of species present at only very low levels prior to FMT6.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Muyzer, G., de Waal, E. C., & Uitterlinden, A. G. (1993) · Applied and Environmental Microbiology · doi:10.1128/aem.59.3.695-700.1993 · Cited by 11,429
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785 · cited 1×
“Many Firmicutes produce butyrate and are postulated to be involved in obesity in humans and murine models.(32,33) Short chain length fatty acids (SCFAs), especially butyrate, have also been shown to play a critical role in maintaining integrity of the colonic epithelium and regulation of the mucosal immune responses.”
BackgroundDiversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
Ecological and Evolutionary Forces Shaping Microbial Diversity in the Human Intestine
Ley, R. E., Peterson, D. A., & Gordon, J. I. (2006) · Cell · doi:10.1016/j.cell.2006.02.017 · Cited by 3,358 · cited 1×
“These bacteria are well-known dominant members of human fecal microbiota,(16) and these phyla are thought to play major ecologic roles in establishment and maintenance of gut homeostasis.(30) A lack of Bacteroides sp.”
BackgroundDevelopment of the Human Infant Intestinal Microbiota
Palmer, C., Bik, E. M., DiGiulio, D. B., Relman, D. A., & Brown, P. O. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050177 · Cited by 2,877
Edwards, U., Rogall, T., Blöcker, H., Emde, M., & Böttger, E. C. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.19.7843 · Cited by 2,724 · cited 1×
“primers Bact-8F (5’-AGAGTTTGATCCTGGCTCAG-3’) [25] 5′ end-labeled with 6-”
Dethlefsen, L., Huse, S., Sogin, M. L., & Relman, D. A. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060280 · Cited by 2,361
Clostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 4×
“Unfortunately, the same problem is encountered by others treating this disease.(1) In the studies reported here, we used a molecular approach to gain a better understanding of the bacterial composition of the GI tract in a CDAD patient.”
BackgroundInfluentialDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 2×
“However, the composition and species richness of intestinal tract microbiota in individuals with CDAD and recurrent CDAD were found to be markedly different from controls.(14) The reestablishment of the normal composition of the intestinal flora has long been hypothesized to be a curative approach for the recurrent CD…”
BackgroundKyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804
Breaking The Cycle: Treatment Strategies for 163 Cases of Recurrent Clostridium Difficile Disease
McFarland, L. V., Elmer, G. W., & Surawicz, C. M. (2002) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05839.x · Cited by 724 · cited 2×
“Most cases of the CDAD respond to the treatment with metronidazole or vancomycin.(1,10,11) However, recurrence of the infection occurs in about 20% of cases, and it is typically caused by regrowth of vegetative C.”
BackgroundDial, S. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040876 · Cited by 577
Clostridium difficile: its disease and toxins
Lyerly, D. M., Krivan, H. C., & Wilkins, T. D. (1988) · Clinical Microbiology Reviews · doi:10.1128/cmr.1.1.1 · Cited by 576 · cited 1×
“difficile strains producing exotoxins are pathogenic.(1,7,8) The rising mortality of CDAD since 2000 has been associated with emergence of the BI/NAP-1/027 strain that is characterized by markedly increased production of toxins A and B, resistance to fluoroquinolones, and production of binary toxin.”
BackgroundImpact of Clostridium difficile on Inflammatory Bowel Disease
Issa, M., Vijayapal, A., Graham, M. B., Beaulieu, D. B., Otterson, M. F., Lundeen, S., Skaros, S., Weber, L. R., Komorowski, R. A., Knox, J. F., et al. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.028 · Cited by 570
Incidence of Clostridium difficile Infection in Inflammatory Bowel Disease
Rodemann, J. F., Dubberke, E. R., Reske, K. A., Seo, D. H., & Stone, C. D. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.12.027 · Cited by 522
Aas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518
BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS
Tvede, M., & Rask-Madsen, J. (1989) · The Lancet · doi:10.1016/s0140-6736(89)92749-9 · Cited by 491 · cited 1×
“An attempt to examine this treatment option in more detail was made in a small study by Tvede and Rask-Madsen in 1989.(18) These investigators studied 6 patients with recurrent CDAD and treated them with bacteriotherapy (fecal transplantation) by using fecal enemas or rectal instillation of mixtures of colonic bacteri…”
BackgroundMolecular analysis of the gut microbiota of identical twins with Crohn's disease
Dicksved, J., Halfvarson, J., Rosenquist, M., Järnerot, G., Tysk, C., Apajalahti, J., Engstrand, L., & Jansson, J. K. (2008) · The ISME Journal · doi:10.1038/ismej.2008.37 · Cited by 459 · cited 3×
“To confirm the identities of the bacterial species corresponding to the dominant TRFs, cloning and sequencing of 16S rRNA genes from the fecal extracts were done as described.(16) DNA from the samples were amplified by using the PCR, and general bacterial primers Bact-8F(28) and 926R(26) by using earlier described rea…”
MethodSelf-citationBacteriotherapy for chronic relapsing Clostridium difficile in six patients
Tvede, M. (1989) · The Lancet · Cited by 290
Rationale for the luminal provision of butyrate in intestinal diseases
Wächtershäuser, A., & Stein, J. (2000) · European Journal of Nutrition · doi:10.1007/s003940070020 · Cited by 258 · cited 2×
“Limited SCFA availability to colonocytes has been proposed to play a role in pathogenesis in ulcerative colitis,(35) and administration of SCFAs has been proposed for a variety of inflammatory conditions affecting the intestine.(34) From a therapeutic standpoint, the patient in this study had a remarkably rapid and co…”
BackgroundApproach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis.
Tedesco, F. J., Gordon, D., & Fortson, W. C. (1985) · PubMed · Cited by 217
The starved colon—Diminished mucosal nutrition, diminished absorption, and colitis
Roediger, W. E. W. (1990) · Diseases of the Colon & Rectum · doi:10.1007/bf02051922 · Cited by 214 · cited 1×
“Short chain length fatty acids (SCFAs), especially butyrate, have also been shown to play a critical role in maintaining integrity of the colonic epithelium and regulation of the mucosal immune responses.(34,35) Interestingly, rectal administration of SCFAs has been used successfully to treat antibiotic-associated dia…”
BackgroundRelapsing Clostridium difficile Enterocolitis Cured by Rectal Infusion of Normal Faeces
Schwan, A., Sjolin, S., Trottestam, U., & Aronsson, B. (1984) · Scandinavian Journal of Infectious Diseases · doi:10.3109/00365548409087145 · Cited by 201
Schwiertz, A., Hold, G. L., Duncan, S. H., Gruhl, B., Collins, M. D., Lawson, P. A., Flint, H. J., & Blaut, M. (2002) · Systematic and Applied Microbiology · doi:10.1078/0723-2020-00096 · Cited by 193 · cited 1×
“Ruminococcaceae and Anaerostipes species are a subgroup within the Clostridium coccoides known to produce butyrate.(31) Another butyrate- producing bacterium (represented by TRF 274) also became more abundant 14 days post transplantation.”
BackgroundPersky, S. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)02095-5 · Cited by 179 · cited 1×
“difficile infection.(21,29) The patient had her first solid bowel movement on the second day after the treatment and developed constipation in the initial months after the procedure.”
BackgroundProton pump inhibitor therapy is a risk factor for Clostridium difficile ‐associated diarrhoea
YEARSLEY, K. A., GILBY, L. J., RAMADAS, A. V., KUBIAK, E. M., FONE, D. L., & ALLISON, M. C. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03015.x · Cited by 145
The Microecology of Clostridium difficile
Wilson, K. H. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/16.supplement_4.s214 · Cited by 142 · cited 1×
“difficile.(13,14) Moreover, CDAD is likely a dramatic consequence of a disruption, or imbalance of the commensal gut microbiota that normally exists in a mutualistic relationship with the host.”
BackgroundBacterial Interference Between Clostridium difficile and Normal Fecal Flora
Rolfe, R. D., Helebian, S., & Finegold, S. M. (1981) · Journal of Infectious Diseases · doi:10.1093/infdis/143.3.470 · Cited by 141 · cited 1×
“difficile proliferation.(23) It is likely that the atypical bacterial populations present, consisting mainly of species stains representatives of Veillonella, Clostridium, Lactobacillus, Streptococcus, and unclassified bacteria most similar to Erysipelothrix, were, in part, owing to C.”
BackgroundDicksved, J., Flöistrup, H., Bergström, A., Rosenquist, M., Pershagen, G., Scheynius, A., Roos, S., Alm, J. S., Engstrand, L., Braun-Fahrländer, C., et al. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.02223-06 · Cited by 138 · cited 3×
“The 16S rRNA genes were PCR-amplified from each DNA extract (2 technical replicates per extract) using the general bacterial primers Bact-8F (50-AGAGTTTGATCCTGGCTCAG-30) [25] 50 end-labeled with 6-carboxyfluorescein (6–FAM), and 926r (50-CCGTCAA TTCCTTTRAGTTT-30)26 using conditions described elsewhere.(15) The amounts…”
MethodSelf-citationSpigaglia, P., & Mastrantonio, P. (2004) · Journal of Medical Microbiology · doi:10.1099/jmm.0.45682-0 · Cited by 107 · cited 1×
“difficile strains producing exotoxins are pathogenic.(1,7,8) The rising mortality of CDAD since 2000 has been associated with emergence of the BI/NAP-1/027 strain that is characterized by markedly increased production of toxins A and B, resistance to fluoroquinolones, and production of binary toxin.”
BackgroundJernberg, C., Sullivan, Å., Edlund, C., & Jansson, J. K. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.1.501-506.2005 · Cited by 95
Self-citationA. GUSTAFSSON, S. L.-T. (1998) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365529850171666 · Cited by 88 · cited 1×
“difficile-induced pseudomembranous colitis.(36) Limited SCFA availability to colonocytes has been proposed to play a role in pathogenesis in ulcerative colitis,(35) and administration of SCFAs has been proposed for a variety of inflammatory conditions affecting the intestine.”
BackgroundClostridium difficile and inflammatory bowel disease.
Greenfield, C., Aguilar Ramirez, J. R., Pounder, R. E., Williams, T., Danvers, M., Marper, S. R., & Noone, P. (1983) · Gut · doi:10.1136/gut.24.8.713 · Cited by 85
Community Structure of Actively Growing Bacterial Populations in Plant Pathogen Suppressive Soil
Hjort, K., Lembke, A., Speksnijder, A. G. C. L., Smalla, K., & Jansson, J. K. (2006) · Microbial Ecology · doi:10.1007/s00248-006-9120-2 · Cited by 79 · cited 1×
“The PCR products were digested with restriction enzyme HaeIII and the resulting fragments were separated on an ABI 3730 capillary sequencer (Applied Biosystems, Foster City, CA) as earlier described.(27) The sizes of the fluorescently labeled fragments were determined by comparison with the internal GS ROX-500 size st…”
MethodSelf-citationStabler, R. A., Dawson, L. F., Phua, L. T. H., & Wren, B. W. (2008) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47743-0 · Cited by 69 · cited 1×
“The rising mortality of CDAD since 2000 has been associated with emergence of the BI/NAP-1/027 strain that is characterized by markedly increased production of toxins A and B, resistance to fluoroquinolones, and production of binary toxin.(9) Most cases of the CDAD respond to the treatment with metronidazole or vancom…”
BackgroundPast, Present, and Future Therapies for Clostridium difficile–Associated Disease
McCoy, D., Kuyumjian, A., Wynd, M. A., & Cicogna, C. E. (2006) · Annals of Pharmacotherapy · doi:10.1345/aph.1h332 · Cited by 46 · cited 1×
“Most cases of the CDAD respond to the treatment with metronidazole or vancomycin.(1,10,11) However, recurrence of the infection occurs in about 20% of cases, and it is typically caused by regrowth of vegetative C.”
Background
Cited by
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
“Other important clinical applications of metagenomic analyses include probiotic treatments [94,95] and microbiome transplantation [96-99] for gastrointestinal diseases.”
BackgroundDiversity, stability and resilience of the human gut microbiota
Lozupone, C. A., Stombaugh, J. I., Gordon, J. I., Jansson, J. K., & Knight, R. (2012) · Nature · doi:10.1038/nature11550 · Cited by 5,533
Self-citationThe impact of the gut microbiota on human health: an integrative view
Clemente, J. C., Ursell, L. K., Parfrey, L. W., & Knight, R. (2012) · Cell · doi:10.1016/j.cell.2012.01.035 · Cited by 3,710
“Khoruts et al. showed how transplanting the microbial community from a healthy donor to a patient suffering from Clostridium difficileassociated disease (CDAD) significantly modified the bacterial composition in the patient (Khoruts et al., 2010).”
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
Human Genetics Shape the Gut Microbiome
Goodrich, J. K., Waters, J. L., Poole, A. C., Sutter, J. L., Koren, O., Blekhman, R., Beaumont, M., Van Treuren, W., Knight, R., Bell, J. T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.09.053 · Cited by 3,164
“Because the microbiome can be modified for therapeutic applications (Borody and Khoruts, 2012; Hamilton et al., 2013; Khoruts et al., 2010; van Nood et al., 2013), it constitutes an attractive target for manipulation.”
Metadata
- Authors
- Khoruts, A., Dicksved, J., Jansson, J. K., & Sadowsky, M. J.
- Affiliations
- University of Minnesota (US)
- Swedish University of Agricultural Sciences (SE)
- Lawrence Berkeley National Laboratory (US)
- Corresponding author
- Khoruts, Alexander
- Venue
- Journal of Clinical Gastroenterology
- Published
- 2010-05
- Volume
- 44
- Issue
- 5
- Pages
- 354-360
- ISSN
- 0192-0790 (ISSN-L)
- OpenAlex
- W2095040140
- Cited by
- 649
- References
- 37
- Citations by year
- 2026: 6 · 2025: 15 · 2024: 22 · 2023: 14 · 2022: 13 · 2021: 26 · 2020: 29 · 2019: 41 · 2018: 49 · 2017: 49 · 2016: 53 · 2015: 49 · 2014: 69 · 2013: 88 · 2012: 47
- FWCI
- 44.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Gastroenterology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Clostridium difficile-associated diarrhea, fecal microbiota transplantation, gut microbiota composition, colonic microbiota, Firmicutes, Bacteroidetes, Bacteroides, butyrate-producing bacteria, antibiotic-associated diarrhea
- MeSH terms
- Enterocolitis, Pseudomembranous, Feces, Female, Follow-Up Studies, Humans, Middle Aged, Polymorphism, Restriction Fragment Length, RNA, Ribosomal, 16S, Clostridioides difficile, Sequence Analysis, RNA, Metagenome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.